A Contemporary Review of the Use of Extracorporeal CytoSorb^® Hemoadsorption Therapy in Patients with Infective...

Area of Science:

• Cardiology
• Critical Care Medicine
• Surgical Innovation

Background:

• Infective endocarditis (IE) is a severe condition with high mortality, often requiring cardiac surgery.
• Cardiopulmonary bypass during surgery can exacerbate organ dysfunction and mortality due to inflammation and ischemia-reperfusion injury.
• Extracorporeal hemoadsorption using CytoSorb has been proposed to mitigate these adverse effects in IE patients.

Purpose of the Study:

• To systematically evaluate the clinical evidence for CytoSorb hemoadsorption in IE patients undergoing cardiac surgery.
• To analyze the impact of CytoSorb on hemodynamics, organ dysfunction, and mortality.
• To discuss the rationale and future perspectives of this adjuvant therapy.

Main Methods:

• Review of contemporary findings on CytoSorb hemoadsorption in IE.
• Analysis of studies focusing on clinical outcomes related to cardiac surgery with cardiopulmonary bypass.
• Discussion of the underlying mechanisms of inflammation and organ injury.

Main Results:

• Current literature lacks systematic evaluations of CytoSorb's effect on clinical outcomes in IE.
• Evidence regarding the impact on hemodynamics, organ dysfunction, and mortality remains to be consolidated.
• The rationale for using CytoSorb is based on its ability to remove inflammatory mediators.

Conclusions:

• Further systematic research is needed to establish the efficacy of CytoSorb hemoadsorption in IE patients.
• Clinical trials are essential to determine the definitive impact on patient outcomes.
• CytoSorb represents a potential adjunctive therapy warranting continued investigation in this high-risk population.